Poly(ADP-ribose) polymerase 1 Searches DNA via a ‘Monkey Bar’ Mechanism

Johannes Rudolph1, Jyothi Mahadevan1, Pam Dyer1,2, Karolin Luger1,2

1Department of Chemistry and Biochemistry, University of Colorado Boulder, Boulder, CO 80309, USA.
2Howard Hughes Medical Institute, University of Colorado Boulder, Boulder, CO 80309, USA.
Corresponding author. Email: karolin.luger@colorado.edu

Abstract

Poly(ADP-ribose) polymerase 1 (PARP1) is both a first responder to DNA damage and a chromatin architectural protein. How PARP1 rapidly finds DNA damage sites in the context of a nucleus filled with undamaged DNA, to which it also binds, is an unresolved question. Here we show that PARP1 association with DNA is diffusion-limited, and release of PARP1 from DNA is promoted by binding of an additional DNA molecule that facilitates a “monkey bar” mechanism, also known as intersegment transfer. The WGR-domain of PARP1 is essential to this mechanism, and a point mutation (W589A) recapitulates the altered kinetics of the domain deletion. Demonstrating the physiological importance of the monkey bar mechanism for PARP1 function, the W589A mutant accumulates at sites of DNA damage more slowly following laser micro-irradiation than wild-type PARP1. Clinically relevant inhibitors of PARP1 did not alter the rate or mechanism of the release of PARP1 from DNA.

Introduction

Poly(ADP-ribose) polymerase 1 (PARP1) serves as a first responder to DNA damage and is the founding member and most abundant representative of the large family of diphtheria toxin-like ADP-ribosyltransferases (ARTDs). Binding to either single or double-strand DNA breaks (SSBs or DSBs) enzymatically activates PARP1 to use NAD⁺ in polymerizing long chains of poly(ADP)-ribose (PAR) onto itself and other nuclear acceptor proteins such as histones and DNA repair proteins. These PAR chains then recruit the appropriate DNA repair machinery containing PAR-binding motifs. PARP1 is of special interest because it is a validated target for cancer therapy. Most notably, olaparib and rucaparib are in clinical use for treatment of ovarian and/or breast cancer in BRCA1/2 negative patients, and there are many on-going phase III clinical trials for inhibitors of PARPs either as monotherapy or in combination with chemo- or radiotherapy.

Overall, the domain structures of the 16 members of the ARTD family are quite diverse, but they all share a common catalytic core domain (~ 40 kDa). Clinically relevant inhibitors of PARP1 bind in the catalytic domain. The N-terminal region of PARP1 contains five additional domains; three Zn-finger domains, an automodification domain that contains a BRCT-fold, and a WGR domain (Fig 1A). Seminal work from the Pascal laboratory has provided a molecular understanding of how Zn1, Zn2, Zn3, and the WGR domain collaborate to recognize DNA strand breaks in a structure-specific and sequence-independent manner, and subsequently activate the catalytic activity of PARP1. Zn1 and Zn2 separately, and together in the context of an SSB, bind one DNA end each using two points of contact, termed the phosphate backbone.
grip and the base stacking loop. In the context of a DSB, this grip-loop interaction mode is maintained by Zn1, while the Zn3 and WGR domains make additional contacts to the DNA (Fig 1B)\textsuperscript{15}. Importantly, stepwise assembly of the different domains of PARP1 on DNA leads to the destabilization of the helical subdomain (HD) of the catalytic domain, which results in activation of its ADP-ribosyl transferase activity\textsuperscript{14,16,17}.

In cells, PARP1 is known to contribute to many types of DNA repair mechanisms, including base excision repair, homologous recombination, nucleotide excision repair, and alternative non-homologous end-joining\textsuperscript{18}. In vitro, PARP1 is activated by a wide variety of DNA damage models including nicks, gaps, blunt ends, 5’- or 3’- extensions, all with or without a 5’-phosphate\textsuperscript{19}. There is now clear evidence from multiple laboratories that PARP1 also binds tightly to undamaged DNA. For example, the Kraus laboratory has shown that PARP1 binds to and condenses intact chromatin, represses Pol II-dependent transcription, and is activated for auto-PARylation\textsuperscript{20}. We have previously shown that PARP1 serves as a chromatin architectural protein and interacts tightly (K\text{d} \sim \text{nM}) with and is activated by various nucleosome constructs\textsuperscript{21,22}. Additionally, atomic force microscopy has shown that PARP1 binds not only to DNA ends or specific nicks, but also has significant affinity for undamaged DNA\textsuperscript{23}. Most recently, single molecule tightrope assays have demonstrated that PARP1 interacts with and moves along undamaged DNA\textsuperscript{24}.

Thus PARP1 faces a similar ‘speed-stability’ paradox\textsuperscript{25–27} as transcription factors that need to find their target recognition site in an overwhelming excess of non-specific sites for which they also have significant affinity. PARP1 must rapidly search the genome for damaged DNA, yet it has significant affinity for the billions of base pairs of undamaged DNA that are present at concentrations of \textsim 100 \text{mg/mL} in the nucleus\textsuperscript{28}. In fact, laser micro-irradiation experiments in live cells have shown that PARP1 significantly accumulates at DNA damage sites in less than 10 seconds\textsuperscript{29}. The conundrum is that repeated cycles of release of PARP1 from undamaged DNA, random diffusional collisions, and rebinding to a different location may not be fast enough to explain how PARP1 can rapidly localize to sites of DNA damage. Various models have been put forth and tested for explaining how “facilitated diffusion” could accelerate this search process, all of which recognize the importance, as opposed to hindrance, of non-specific binding to DNA for efficient site localization\textsuperscript{27,30–32}. These models include binding followed by one-dimensional sliding along DNA, hopping to a near-by site in the same chain, and intersegment transfer via an intermediate loop that is formed when the protein binds two different DNA sites at the same time. While some localized sliding along DNA has been reported for PARP1\textsuperscript{23}, a more thorough kinetic characterization of binding to and dissociation from DNA is needed in order to address how PARP1 can efficiently localize to sites of DNA damage to initiate repair.

PARP1 has been found to associate more tightly with DNA in vivo in the presence of clinically relevant inhibitors. This phenomenon, known as PARP “trapping”\textsuperscript{10,33–36} is thought to be in part responsible for the clinical effects of PARP inhibitors and has been used to explain the numerous discrepancies between in vitro inhibition of PARP1 vs. potency in preclinical models. For example, talazoparib is 100-fold more potent at trapping PARP1 on DNA and >50-fold more potent at killing cancer cells than rucaparib and olaparib, although the apparent IC-50’s for all three compounds are quite similar (1 – 5 nM)\textsuperscript{34}. Further complicating matters, extensive biochemical investigations of PARP1 trapping failed to provide evidence for an allosteric interaction between DNA- and inhibitor-binding\textsuperscript{37}, suggesting that trapping is due solely to inhibition of catalytic activity (but see \textsuperscript{16}). Thus an evaluation of PARP inhibitors in a quantitative assay that measures DNA binding and release has the potential to shed further light on this controversial issue.
Here we report on the kinetics of association and dissociation of PARP1 with DNA. We find that association of PARP1 with DNA is extremely fast, and that dissociation depends on the formation of a ternary complex where a second DNA molecule binds before release of the original DNA. We find that the WGR-domain, more specifically the conserved residue Trp589, is essential for triggering DNA-dependent release of DNA from PARP1, and we demonstrate the importance of this mechanism of DNA release for the accumulation of PARP1 at sites of DNA damage in the cell. Finally, we find that clinically relevant inhibitors do not perturb the rate or mechanism of release of DNA from PARP1.

Materials and Methods

Materials
NAD$^+$ was obtained from Sigma. Olaparib, veliparib, niraparib, and talazoparib were obtained from Selleck. DNA oligonucleotides and their complementary strands were obtained from IDT: p18mer: 5’-phosphate-GGGTTGCGGCCGCTTGGG-3’ Labeled oligonucleotides with a 5’-fluorescein dye (*) were also obtained from IDT. Double-stranded fragments were prepared by annealing at 100 µM DNA in 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 0.1 mM EDTA. The DNA was heated to 95°C for 5 min and then slowly cooled at 0.1°C/second to 4°C. Annealing was confirmed by 10% (wt/vol) native TBE-PAGE at 200 V for 30 minutes.

Cloning of Deletion Constructs $\Delta$Zn1, $\Delta$Zn2, $\Delta$Zn3, and $\Delta$WGR of PARP1
The pET28a vector encoding cDNA of full length human PARP1 was used to design constructs lacking various domains of PARP1 following the method outlined in Hansson et al. Briefly, primer 1 was designed as a reverse complement of the sequence that corresponds to 20-25 bases upstream of the DNA sequence to be deleted, followed by 20-25 bases corresponding to the downstream sequence. Primer 2 corresponds to the complementary strand. These primers were used in a PCR reaction to loop out the DNA encoding individual domains of PARP1: $\Delta$Zn1 (M1-K97), $\Delta$Zn2 (G96-linker-K207), $\Delta$n3 (G215-linker-A367), and $\Delta$WGR (N517-linker-L655). After PCR, DpnI digestion was used to degrade the template plasmid and was then transformed to generate clones. Next, a linker DNA sequence encoding amino acids LLA(GS)4GAAL was inserted in place of the deleted domain using partially overlapping primers comprising the entire sequence of the insert followed by 20-25 bases of the downstream sequence. Thereafter, another step of insertion of linker DNA sequence encoding amino acids ALA (GS)5GLAL upstream of the previous insert was performed in a similar manner. The plasmids used to express various domain deletion PARP1 mutants eventually all contained the 30 amino acid linker ALA (GS)5GLALLA(GS)5GAAL in place of the deleted PARP1 domain. The W589A mutant of PARP1 was generated using QuikChange Mutagenesis (Agilent) following the manufacturer’s instructions. All constructs were verified by DNA sequencing of the entire PARP1 gene.

Expression and Purification of PARP1
Wild-type PARP1, all deletion constructs, and the W589A mutant of PARP1 were expressed and purified from E. coli as previously described with the minor modification that PARP1 was eluted from the nickel-NTA column using a gradient from 20 – 400 mM imidazole.

Activity and Stability Measurements of PARP1
PARylation activity was evaluated by incubating 1 µM PARP1 with 1 µM p18mer and 500 µM NAD$^+$ in 50 mM Tris- HCl (pH 7.5), 50 mM NaCl, and 1 mM MgCl$_2$, for 5 min. Reactions were quenched in Laemmli buffer, boiled for 5 min, and then resolved on SDS-PAGE (4 – 20%).
PARP1 stability was evaluated using the Protein Thermal Shift Dye Kit from Applied Biosystems
and a BioRad C1000 ThermalCycler with a CFX96 RealTime module.

**Stopped-Flow Fluorescence Anisotropy**

A SX20 Stopped-Flow Spectrometer (Applied Photophysics) was used for measuring
fluorescence anisotropy using an excitation wavelength of 485 nm and cut-off filters in the
parallel and perpendicular detectors at 515 nm. Association reactions were measured by mixing
equal volumes of p18mer* (60 nM) with 3 – 8 different concentrations of PARP1 (60 – 250 nM)
and monitoring the anisotropy at 20°C for 25 ms. All indicated concentrations are after mixing.
Although PARP1 can bind to both ends of p18mer* (and p18mer) simultaneously15, we treat
each DNA oligomer as one equivalent (not two) because fluorescence anisotropy detects only
the first binding event. Control reactions used for determining background signal lacked PARP1.
For measuring dissociation, a pre-formed complex of PARP1 (37 nM) and p18mer* (50 nM) was
mixed with 5 – 15 different concentrations of p18mer (100 nM – 8 µM) and anisotropy was
monitored at 20°C for 1 – 5 s. Control reactions for determining background signal lacked
p18mer. All reactions were performed in 50 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM MgCl2,
0.1 mM EDTA, and 0.01% IGEPAL. For all stopped-flow reactions, data were collected in log
mode, and 10 – 12 shots were averaged for each different concentration of reagents. All
experiments consisting of series of different concentrations of PARP1 (for association) or of
p18mer (for dissociation) were performed on at least three different days with at least two
different preparations of protein. Dissociation experiments in the presence of inhibitors (50 nM)
of PARP1 were compared to DMSO controls (<2 %v/v).

**Data Fitting**

Data were initially analyzed for fitting to single exponential kinetics using the software from
Applied Photophysics (ProDataTSV). Global analysis incorporating multiple different
concentrations of protein or competing DNA were performed using KinTek Explorer (KinTek
Corporation). For association kinetics, control reactions in the absence of protein were used to
determine the baseline, and the maximum anisotropy signal (identical at all protein
concentrations) was used to convert anisotropy units to concentration values. For dissociation
kinetics, control reactions in the absence of DNA were used to determine the baseline, and the
maximum anisotropy signal at high concentrations of p18mer (1 – 4 µM) were used to convert
anisotropy units to concentration values. For clarity, only a subset of the concentrations used
experimentally are shown in the figures.

**Fluorescence accumulation of GFP-PARP1 after laser microirradiation**

Mammalian expression plasmid (pEGFP-C3, 250 ng/20,000 cells) encoding full-length GFP-
tagged human PARP1 was transfected using jetPEI (Polyplus Transfection) into wild type
mouse embryo fibroblasts (MEFs) cultured in DMEM supplemented with 50µg/ml of gentamicin
and 10% FBS, as previously described (Mahadevan et al, in preparation). Cells were sensitized
with Hoechst 33342 (Invitrogen) (10µg/ml) for 10 min prior to induction of DNA damage using a
405 nm diode laser (100% power for 1 s). Cells were imaged for 1 – 5 min using excitation at
488 nm within a heated environmental chamber set to 37°C and 5% CO2 (Nikon A1R confocal
laser scanning; frame size of 512 X 512). Analysis of the fluorescent images was carried out
using custom codes in MATLAB and Mathematica to allow derivation of the diffusion coefficient
\( D_{eff} \) and mobile fraction of PARP1 (F) (Mahadevan et al, in preparation).

**Results**

Association of PARP1 with DNA is extremely fast
We began our investigations by measuring the rate of association of PARP1 with DNA. Varying concentrations of PARP1 (60 – 250 nM) were mixed in a stopped-flow apparatus with fixed concentrations (30 nM) of a fluorescently labeled model of a double-strand break with a 5'-phosphate (p18mer*). Addition of protein results in an increase in fluorescence anisotropy that is not observed by addition of buffer alone (Fig. 2A). The data at all concentrations of PARP1 could be fitted with a single exponential to yield $k_{obs}$ with very good residuals (Fig. 2A). Under idealized experimental conditions wherein the concentration of PARP1 greatly exceeds the concentration of p18mer*, one would expect a replot of $k_{obs}$ vs. the concentration of PARP1 to yield a straight line, as was indeed observed here (Fig. 2A, inset). The slope of such a line equals the apparent second order rate constant of association whereas the y-intercept equals the first-order rate constant of dissociation. To analyze the data more rigorously, we used Kintek Explorer, a powerful fitting program that allows for global model-dependent fitting that does not require adherence to limiting conditions (Fig. 2B). Our analysis yields a $k_1$ of 3.1 nM$^{-1}$s$^{-1}$ (Scheme 1, Table 1). The rate of dissociation ($k_1$) could not be determined from this experiment since no significant dissociation occurs over the 25 ms time course of the experimental observation. Using global fitting, we could derive an upper bound for $k_1$ of 10 s$^{-1}$. Thus the true equilibrium dissociation constant ($K_D$) of a double-strand break under these conditions is <3 nM (Supp. Table 1), lower than the previously reported $K_D$s of 31 nM$^{21}$, 14 nM$^{40}$, and 97 nM$^{16}$ (see Discussion).

Dissociation of PARP1 from DNA requires binding of a second DNA molecule

Because we were unable to determine the rate of DNA dissociation from PARP1 in the previous experiment, we designed an experiment to explicitly measure this rate using competition. Here we pre-form a complex between PARP1 and fluorescently labeled DNA and use an excess of unlabeled DNA to compete away the labeled DNA and prevent its re-association with PARP1. We began these investigations by first performing a label-swap experiment to ensure that unlabeled p18mer behaves similarly to fluorescein labeled p18mer*. Since the experimental read-out is based on the change in fluorescence anisotropy of p18mer*, we used a fixed and limiting concentration of total labeled DNA such that no excess p18mer* is present. PARP1 (37 nM), pre-bound to either p18mer or p18mer* (25 nM) was mixed with 25 nM p18mer* or p18mer (respectively) in a stopped-flow apparatus. Dissociation of p18mer or p18mer* (followed by binding of the competitor) was monitored by an increase or decrease in fluorescence anisotropy, respectively (Supp. Fig. 1). The similarity of these two experiments is best visualized by plotting the sum of the signal to generate a flat line equal to the probe concentration (25 nM), a pseudo-residual indicating that p18mer and p18mer* are kinetically indistinguishable in our assay.

In order to probe the mechanism of DNA dissociation from PARP1, we next varied the concentrations of competitor DNA. Under ideal experimental conditions, where the concentration of competitor DNA (>500 nM) greatly exceeds the probe concentration (25 nM), and assuming the simplest model wherein the rate of dissociation is rate-determining ($k'_1$ [DNA] >> $k_1$, Scheme 2), we expect that $k_{obs}$ would be independent of the concentration of competitor DNA. PARP1 (37 nM), pre-bound to p18mer* (25 nM), was mixed with various concentrations of competitor DNA (p18mer, 500 nM – 4000 nM) in a stopped-flow apparatus and dissociation of p18mer* was monitored by a decrease in fluorescence anisotropy (Fig. 3). The data could be fitted to a single exponential to yield $k_{obs}$ with very good residuals (Fig. 3). However, as seen in the data in Fig. 3 by comparing dissociation in the presence of 2.2 vs 4 µM DNA, and in the replot of $k_{obs}$ vs. multiple concentrations of competitor DNA, $k_{obs}$ increases at increasing concentrations of competitor DNA (Fig. 3, inset). Additionally, attempts to fit these data with Scheme 2 in Kintek Explorer yielded very poor fits and highly skewed residuals (Supp. Fig. 2).
Thus a different kinetic scheme is needed to fit these data, one where competitor DNA is actively contributing to the dissociation of the pre-bound p18mer*.

The simplest model to explain active participation of a competitor DNA in the dissociation of an already bound DNA is formation of a ternary complex wherein the competing DNA binds to PARP1 prior to the dissociation of the pre-bound DNA (Scheme 3). This model consists of four rate constants: \( k_2 \) (formation of the ternary complex), \( k_{-2} \) (release of the competing DNA to regenerate the pre-bound complex), \( k_3 \) (release of the pre-bound DNA to generate PARP1 only bound to the competing DNA), and \( k_{-3} \) (re-formation of the ternary complex). Experimentally, both the starting pre-bound complex and the ternary complex are assigned a high anisotropy, whereas the final complex bound only to competing, unlabeled DNA is assigned a low anisotropy. In order to best constrain the four rate constants required to describe Scheme 3, we used a broader range of competing DNA concentrations (50 nM – 4000 nM). Also, each concentration series was independently determined and fitted using Kintek Explorer at least three times. Representative fits of this model to the data are shown in Fig. 4, and the residuals indicate very good agreement between the data and this model, even at low concentrations of competitor DNA where \( k_{\text{obs}} \) does not fit to a simple exponential and the apparent extent of exchange is significantly lower than at high concentrations. The aggregated rate constants are shown in Table 1 and the derived dissociation constants are shown in Supp. Table 1. The quality of the fits with the kinetic model in Scheme 3 provides strong support for the requisite formation of a ternary complex in the dissociation of DNA from PARP1.

The second order rate constant of association for the second DNA molecule is 0.043 nM\(^{-1}\)s\(^{-1}\) is almost two orders of magnitude lower than that for association of the first DNA oligomer. The \( K_D \) for the second DNA strand is 2600 nM, explaining why this complex would be rarely if ever detected under typical experimental conditions performed at nanomolar concentrations of PARP1. Note that the rates of association and dissociation for the second DNA are not "symmetrical" (i.e. \( k_2 \neq k_{-3} \) and \( k_{-2} \neq k_3 \)). This asymmetry is most pronounced in the comparison between \( k_{-2} \) and \( k_3 \): the pre-bound DNA is less likely to dissociate than the second competitor DNA. This observation makes intuitive sense in that the newly incoming DNA presumably binds to a different (weaker) site than the originally more tightly bound DNA. Although there is a lack of symmetry in the rate constants, the kinetically derived dissociation constants (\( K_D \)s) are quite similar (Supp. Table 1).

The WGR domain provides the binding site for the second DNA molecule

Formation of a ternary complex with two different DNA molecules bound simultaneously requires two separate DNA binding sites. PARP1 has four domains that are known to contribute to DNA binding: Zn1, Zn2, Zn3, and WGR (Figure 1). In order to identify if one or more of these domains selectively contributes to the formation of the ternary complex required for efficient DNA release, we generated constructs of PARP1 lacking each of these individual domains. To facilitate proper assembly of the remaining domains, we inserted a flexible 30 amino acid linker into each deletion, except for the N-terminal deletion of Zn1. All mutants were purified to near homogeneity and were tested for DNA-dependent PARylation activity (Supp. Fig. 3). As previously reported, Zn1, Zn3, and WGR are essential for catalytic activity, and thus deletion of these domains disrupts PARylation activity. On the other hand, the deletion of the non-essential Zn2 domain does not affect PARylation activity.

We next measured the rates of association to, and dissociation from p18mer* for each of the individual deletions of the DNA-binding domains, using the stopped-flow anisotropy assays described above. As for wild-type PARP1, each deletion construct was assayed at multiple different concentrations of protein or DNA, and the data were analyzed using global fitting in
Kintek Explorer. Despite each construct missing one DNA-binding domain, all four bound to DNA with similar second-order rate constants ($k_1$s, Table 1, Supp Fig. 4A-D). In the dissociation experiment, the Zn deletions ($\Delta$Zn1, $\Delta$Zn2, and $\Delta$Zn3) behaved essentially like wild-type PARP1: increasing competitor DNA concentrations yielded increasing $k_{obs}$, and the data were best described by global fitting of the kinetic model of Scheme 3 with the formation of a ternary complex (Supp Fig. 5A-C, Table 1). In contrast, the $\Delta$WGR mutant behaved dramatically differently; increasing concentrations of competitor DNA did not yield higher $k_{obs}$, and globally the data were best described by Scheme 2 (Fig. 5A, Table 1). In the structure of PARP1 bound to a DSB, Trp589 in the WGR domain stacks against the ribose sugar of the 5’-end of the DNA. Since deletion of the entire WGR domain disrupted formation of the ternary complex, we tested whether the more conservative W589A substitution could recapitulate this effect. PARP1-W589A was prepared (Supp. Fig. 3) and tested in both the association and dissociation assays. The W589A point mutation is properly folded, as the mutant and wild-type PARP1 have identical melting temperatures (43.9 ± 0.3 vs. 43.3 ± 0.3 °C). Similar to what was observed with the deletion of the entire WGR domain, the W589A mutant also bound to free DNA rapidly (Supp. Fig. 6), and released DNA via the simple mechanism in Scheme 2 that is not dependent on binding a second DNA molecule (Fig. 5B, Table 1).

The W589A mutant shows reduced accumulation at sites of DNA damage in cells

In order to test the physiological relevance of the mechanism of DNA-dependent release of DNA from PARP1 revealed in our in vitro experiments, we compared the rate and magnitude of accumulation of wild-type PARP1 with the W589A mutant at sites of DNA damage in cells. Mouse embryo fibroblasts were transiently transfected with GFP-tagged PARP1 (wild-type or W589A), and DNA damage was induced by laser microirradiation at a designated region of interest (ROI) within the nucleus. Accumulation of PARP1 in the ROI was monitored by confocal microscopy for 1 – 5 min and the diffusion coefficient ($D_{eff}$) and magnitude of PARP1 accumulation (F) were derived as recently described (Mahadevan et al., in preparation). As seen in Table 2, the W589A mutant accumulated to a lower level and with a significantly slower diffusion coefficient than wild-type PARP1.

High affinity inhibitors of PARP1 do not alter the rate or mechanism of DNA dissociation

Given the uncertain experimental basis for PARP1 trapping on DNA in cells treated with clinically relevant inhibitors of PARP1, we used the rigorous in vitro assay described above to investigate whether these inhibitors lead to a change in the rate or mechanism of DNA dissociation. We monitored the dissociation of p18mer* from PARP1 by fluorescence anisotropy in the presence of four different tight-binding inhibitors of PARP1, using 1 µM competitor p18mer. The observed dissociation curves were fit with a first order exponential and the calculated rates were essentially identical to the DMSO control for olaparib, veliparib, niraparib, and talazoparib (Fig 6A). To ensure that in the presence of inhibitor, DNA dissociation was still dependent on binding of competitor DNA (Scheme 3), we investigated the DNA concentration dependence of p18mer* dissociation in the presence of talazoparib, the most potent PARP1-trapping compound. The dissociation of p18mer* in the presence of talazoparib (50 nM) was measured at varying concentrations of competitor p18mer (1 – 4 µM) and a concentration-dependent increase in $k_{obs}$ was observed just as for the control without inhibitor (Fig. 6B). We conclude that these inhibitors do not change the rate or mechanism of DNA dissociation from PARP1.

Discussion

Our results regarding the mechanisms of association and dissociation of PARP1 to and from DNA have important implications for our understanding of how PARP1 can move around the
nucleus to scan for DNA damage. In vitro, PARP1 binds to DNA at or above the commonly
accepted diffusion-limited rate\(^ {41} \) of 1 – 2 nM\(^{-1}\)s\(^{-1}\), consistent with its extremely rapid
accumulation at sites of DNA damage in vivo\(^ {29,42} \). In fact, compared to other model systems
using DNA oligomers, PARP1 – DNA association is among the fastest previously reported. For
comparison, the rates of association of eukaryotic mismatch repair complex Msh2-Msh6\(^ {43} \), RNA
polymerase\(^ {44} \), 8-oxoguanine-DNA-glycosylase\(^ {45} \), and papillomavirus E2 protein\(^ {46} \) with double-
stranded DNA are 0.002, 0.004, 0.13, and 0.6 – 1.4 nM\(^{-1}\)s\(^{-1}\), respectively, effectively spanning
three orders of magnitude. The fast association of PARP1 with DNA means that when
dissociation does occur, re-association is most likely to the same site on the same DNA, as
association is faster than diffusion carrying PARP1 away from its original binding site. This
observation suggests that PARP1, like other DNA-binding proteins such as transcription
factors\(^ {25} \), must have a mechanism for moving around the genome that does not rely on simple
dissociation and re-association. Although protein sliding along DNA in one-dimension has
previously been invoked as a potential mechanism for accelerating the search for specific
binding sites\(^ {30} \), more recent publications point out potential difficulties with such a long-distance
sliding model\(^ {47} \), which is even more difficult to envision given the organization of DNA into
nucleosomes in the eukaryotic genome.

Instead, we have found that PARP1 dissociation from DNA is triggered by binding of an
additional DNA oligomer prior to dissociation from the first DNA oligomer. We envision a
“monkey bar” model\(^ {48,49} \), wherein PARP1 moves from one DNA molecule to another DNA
molecule, much like a child swings from bar to bar, transferring one hand at a time. This
mechanism allows PARP1 to effectively scan the genome, moving to new and different sections
of DNA. In the absence of competing DNA, PARP1 would remain effectively stuck at or near
one site given its fast rate of association. We have found that the WGR domain provides the
other weaker “hand” to facilitate the movement from one DNA strand to the next. Based on the
structure of PARP1 bound to a DSB\(^ {15} \), the WGR domain would need to first dissociate from the
bound DNA prior to association with a second different molecule of DNA. Such a model is
consistent with an NMR study that provides evidence for the stepwise assembly of PARP1 on a
site of DNA damage where the Zn1, Zn2, and Zn3 domains engage a DNA molecule prior to
final engagement of the WGR and catalytic domains\(^ {14} \). Thus, one can readily imagine a partial
reversal of this process wherein the WGR domain releases the original DNA to bind the
incoming DNA, followed by release of the original DNA and subsequent rearrangement of the
domain around the newly bound DNA (Figure 7).

A recent study of PARP1 using single molecule DNA tightrope assays provides strong evidence
for such a monkey bar mechanism\(^ {24} \). It was shown that micro-dissociation of one of PARP1’s
multiple DNA binding domains from DNA allows it to bind to a free 37 bp fragment, thus
preventing rebinding of the domain to the tightrope and accelerating overall macro-dissociation.
Our mechanism for DNA-dependent DNA dissociation also provides a compelling explanation
for the wide diversity and significantly weaker dissociation constants previously reported for
PARP1 with DNA\(^ {16,21,40} \); the measured apparent \( K_d \) depends strongly on the experimental
conditions (i.e. [DNA]) under which the experiment is performed, since higher concentrations of
DNA promote release of DNA.

Strong in vitro evidence for a monkey bar mechanism, also known as intersegment transfer,
exists for various other proteins, all of them transcription factors. Kinetic experiments similar to
ours have demonstrated strong dependence of DNA release on additional DNA for cAMP
receptor protein\(^ {50} \) and glucocorticoid receptor\(^ {51} \). NMR methods have demonstrated that both
HoxD9\(^ {51} \) and Oct1\(^ {52} \) can bridge one DNA strand to another. A combination of methods including
NMR, rate measurements, and computational modeling have elegantly demonstrated how Egr1
uses its three Zn fingers to both bind and scan other DNA fragments as it moves between different recognition sites on different DNA molecules. Interestingly, mutagenesis of specific residues in Egr1 was used to shift the equilibrium between binding and scanning modes.

One major caveat to any biochemical investigation of the mechanism of DNA – protein interactions is the artificial nature of a DNA oligomer compared to intact chromatin. This limitation affects studies of PARP1 interactions with DNA in particular because it is quite difficult to prepare completely intact DNA without ends or nicks, preferably wrapped around nucleosomes. Thus, it was important to test the significance of the monkey bar mechanism in a more physiologically relevant model. We have demonstrated the validity of interstrand transfer in vivo by demonstrating that the point mutant W589A, which disrupts DNA-dependent release of DNA, accumulates slower and to a lesser amount than wild-type PARP1 at sites of laser microirradiation (Table 2). The slower accumulation of W589A in cells is a particularly powerful demonstration of the importance of the monkey bar mechanism for PARP1 in finding sites of DNA damage for two reasons. First, the rate of dissociation for W589A from DNA is greater than for wild-type (20 s⁻¹ vs. <10 s⁻¹). Second, the apparent K_D of W589A for DNA is weaker than that of wild-type PARP1 (5 nM vs. <3 nM, respectively). Simplistically, these two observations might suggest that W589A should arrive at sites of DNA damage more rapidly than wild-type PARP1 since its interaction with DNA is not as tight or as long-lived (i.e. it spends less time occupying irrelevant sites); yet we observe the opposite. The monkey bar mechanism provides the explanation for these results: high concentrations of intranuclear DNA allow PARP1 to explore the nucleus so fast. A dysfunctional monkey (W589A) surrounded by a lot of DNA does not move as rapidly. Thus, we have quantitatively demonstrated the importance of intersegment transfer in the accumulation of a DNA-binding protein at its target destination in vivo.

Finally, our results also provide further insight into the much-discussed topic of PARP1 “trapping”, wherein cells treated with inhibitors of PARP1 exhibit a shift of PARP1 from the soluble fraction to a chromatin-associated insoluble fraction. Many cell-based studies have since confirmed the phenomenon of PARP-trapping. Our data showing no effect of four different tight-binding inhibitors of PARP1 on the release of DNA agree with a previous thorough biochemical analysis that also could not find any effects of inhibitors on DNA binding constants or rates of dissociation. Thus, the mechanistic basis for PARP-trapping appears to be more complex than can be reconstituted in vitro.
## Tables

### Table 1: Kinetic parameters for DNA association and dissociation

|        | $k_1$ (nM$^{-1}$s$^{-1}$) | $k_{-1}$ (s$^{-1}$) | $k_2$ (nM$^{-1}$s$^{-1}$) | $k_{-2}$ (s$^{-1}$) | $k_3$ (s$^{-1}$) | $k_{-3}$ (nM$^{-1}$s$^{-1}$) |
|--------|--------------------------|---------------------|---------------------------|---------------------|-----------------|-----------------------------|
| WT     | $3.1 \pm 0.2$            | $< 10$              | $0.043 \pm 0.019$         | $102 \pm 22$        | $9.7 \pm 0.8$   | $0.013 \pm 0.002$           |
| $\Delta$Zn1 | $3.7 \pm 0.4$            | $< 10$              | $0.018 \pm 0.012$         | $97 \pm 19$         | $21 \pm 5$     | $0.027 \pm 0.009$           |
| $\Delta$Zn2 | $4.0 \pm 1.3$            | $< 10$              | $0.073 \pm 0.015$         | $145 \pm 66$        | $15 \pm 4$     | $0.023 \pm 0.007$           |
| $\Delta$Zn3 | $5.5 \pm 0.3$            | $< 10$              | $0.034 \pm 0.013$         | $76 \pm 66$         | $19 \pm 7$     | $0.050 \pm 0.016$           |
| $\Delta$WGR | $2.4 \pm 1.1$            | $18.7 \pm 2.7$      |                           |                     |                |                             |
| W589A  | $4.2 \pm 0.5$            | $20.2 \pm 2.4$      |                           |                     |                |                             |

All values (mean and standard deviation) were derived from global fitting in Kintek Explorer of data from at least three independent experiments performed on different days and using at least two independent preparations of protein. All $k_1$ rate constants were derived using the kinetic model in Scheme 1. All other rate constants came from using the kinetic model in Scheme 3, except for the $k_{-1}$ values for $\Delta$WGR and W589A, which were derived using Scheme 2.

### Supp. Table 1: Thermodynamic parameters for DNA binding to PARP1

|        | $K_1$ (nM) | $K_2$ (nM) | $K_3$ (nM) |
|--------|------------|------------|------------|
| WT     | $< 3.2$    | $2600 \pm 600$ | $700 \pm 100$ |
| $\Delta$Zn1 | $< 2.7$    | $7300 \pm 4800$ | $900 \pm 400$ |
| $\Delta$Zn2 | $< 2.5$    | $2100 \pm 1200$ | $700 \pm 300$ |
| $\Delta$Zn3 | $< 1.8$    | $2600 \pm 1300$ | $400 \pm 100$ |
| $\Delta$WGR | $9.2 \pm 4.7$ |            |            |
| W589A  | $4.9 \pm 1.1$ |            |            |

All values (mean and standard deviation) were derived from the kinetic parameters in Table 1.

### Table 2: Fluorescence Accumulation after DNA Damage

|        | Wild-type | W589A |
|--------|-----------|-------|
| $D_{eff}$ (µm$^2$/s) | $4.3 \pm 0.9$ | $2.2 \pm 0.4$ |
| F      | $53 \pm 6$ | $32 \pm 5$ |
| n      | 18        | 16    |

The differences in values of $D_{eff}$ and F (mean and standard deviation) were determined to be statistically significant using an unpaired t-test ($p < 0.05$).
Figure Legends

Figure 1: A) Schematic of the domains of PARP1; B) DNA binding domains (Zn1, green, Zn3 gray, and WGR, blue) of PARP1 engaging a DNA DSB (red). Residues R34 and F44 of the phosphate backbone grip and the base stacking loop in the Zn1 domain are shown in yellow and W589 in the WGR domain is shown in light blue. Coordinates were taken from 1dqy.

Figure 2: A) Representative measurement of PARP1 association with DNA as monitored by fluorescence anisotropy. Shown are the data in the absence of PARP1 (blue) and in the presence of 83 nM PARP1 (red). The black line shows a first-order exponential fit to the data and the residuals (r) from this fit are shown above. The inset shows a replot of k_{obs} vs. varying concentrations of PARP1 using the mechanism in Scheme 1: 50 nM in blue, 83 nM in green and 133 nM in red. Residuals (r) for the three concentrations are shown in the corresponding colors above.

Figure 3: Representative measurement of PARP1 dissociation from DNA as monitored by fluorescence anisotropy. Shown are the data in the absence of competitor DNA (in blue) and in the presence of 2.2 µM (green) and 4 µM DNA (red). The black line shows a first-order exponential fit to the data and the residuals from these fits are shown in the corresponding colors above. The inset shows a replot of k_{obs} vs. varying concentrations of competitor DNA.

Figure 4: PARP1 dissociation from DNA as monitored by fluorescence anisotropy. Global fitting of six representative concentrations of competitor DNA using the mechanism in Scheme 3: 76 nM (light green), 149 nM (blue), 225 nM (red), 398 nM (violet), 1 µM (dark green), and 4 µM (brown). Residuals for the seven concentrations are shown overlaid in the corresponding colors above.

Figure 5: PARP1 dissociation from DNA as monitored by fluorescence anisotropy. Global fitting of three representative concentrations of competitor DNA using the mechanism in Scheme 2: 0.4 µM in blue, 1.3 µM in green, and 4 µM in red for A) ΔWGR and B) W589A. Residuals for the three concentrations are shown overlaid in the corresponding colors above.

Figure 6: PARP1 dissociation from DNA as monitored by fluorescence anisotropy in the presence of various inhibitors of PARP1. A) Apparent k_{obs} at 1 µM competitor DNA using four different inhibitors (50 nM) (ola = olaparib, veli = veliparib, nira = niraparib, tala = talazoparib). B) Apparent k_{obs} at 1 – 4000 nM competitor DNA for PARP1 alone (red) and PARP1 the presence of 50 nM talazoparib (blue).

Figure 7: Model for the monkey bar mechanism for PARP1 depicting the proposed role of the WGR domain in capturing the second DNA strand prior to release of the originally bound DNA strand and subsequent re-arrangement around the second DNA.

Supplementary Figures

Supp. Fig. 1: Label-swap experiment demonstrating that monitoring p18mer* and p18mer release are kinetically identical. The pseudo-residuals generated by addition of the two signals are centered at the total concentration of the probe DNA (25 nM).

Supp. Fig. 2: PARP1 dissociation from DNA as monitored by fluorescence anisotropy. Global fitting of six representative concentrations of competitor DNA using the mechanism in Scheme 2: 76 nM (light green), 149 nM (blue), 225 nM (red), 398 nM (violet), 1 µM (dark green), and 4
µM (brown). Residuals for the seven concentrations are shown overlaid in the corresponding colors above.

Supp. Fig. 3 SDS-PAGE showing purified PARP1, its deletion constructs and the W589A point mutant. Each construct was also assayed for activity in the presence (+) of NAD+ (200 µM) and one equivalent of p18mer DNA.

Supp. Fig. 4: Association of ∆Zn1, ∆Zn2, ∆Zn3 and ∆WGR with p18mer*. Global fits of the kinetic model in Scheme 1 for three representative protein concentrations (lowest concentration in blue, intermediate concentration in green, highest concentration in red) for each mutant: A) ∆Zn1 (42 nM, 72 nM, 120 nM); B) ∆Zn2 (35 nM, 52 nM, 95 nM); C) ∆Zn3 (50 nM, 83 nM, 133 nM); and D) ∆WGR (37 nM, 74 nM, 129 nM). Residuals for the three concentrations are shown overlaid in the corresponding colors above each plot.

Supp. Fig. 5: Dissociation of ∆Zn1, ∆Zn2, and ∆Zn3 from p18mer*. Global fits of five representative concentrations of competitor DNA are shown for each mutant: 0.15 µM (blue), 0.4 µM (light green), 1 µM (violet), 2 µM (dark green), and 4 µM (red) to the kinetic mechanism in Scheme 3 for A) ∆Zn1, B) ∆Zn2, and C) ∆Zn3. Residuals for the five concentrations are shown overlaid in the corresponding colors above each plot.

Supp. Fig. 6: Association of W589A with p18mer*. A global fit of the kinetic model in Scheme 1 to three representative protein concentrations is shown (38 nM in blue, 51 nM in green, and 63 nM in red).

Acknowledgments
This work was supported by NIH-NCI R01 CA218255-01 and the Howard Hughes Medical Institute.

Competing interests
The authors have no competing interests.

References
(1) Bai, P. (2015) Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance. Mol. Cell 58, 947–958.
(2) Bock, F. J., and Chang, P. (2016) New Directions in PARP Biology. FEBS J. 1–15.
(3) Beck, C., Robert, I., Reina-San-Martin, B., Schreiber, V., and Dantzer, F. (2014) Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3. Exp. Cell Res. 329, 18–25.
(4) Daniels, C. M., Ong, S.-E., and Leung, A. K. L. (2015) The Promise of Proteomics for the Study of ADP-Ribosylation. Mol. Cell 58, 911–924.
(5) De Vos, M., Schreiber, V., and Dantzer, F. (2012) The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol. 84, 137–146.
(6) Mashimo, M., Kato, J., and Moss, J. (2014) Structure and function of the ARH family of ADP-ribose-acceptor hydrolases. DNA Repair (Amst). 23, 88–94.
(7) Morales, J., Li, L., Fattah, F. J., Dong, Y., Bey, E. a, Patel, M., Gao, J., and Boothman, D. a. (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for...
targeting in cancer and other diseases. *Crit. Rev. Eukaryot. Gene Expr.* 24, 15–28.

(8) Karlberg, T., Langelier, M. F., Pascal, J. M., and Schüler, H. (2013) Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling. *Mol. Aspects Med.* 34, 1088–1108.

(9) Teloni, F., and Altmeyer, M. (2016) Survey and summary readers of poly(ADP-ribose):

Designed to be fit for purpose. *Nucleic Acids Res.* 44, 993–1006.

(10) Tangutoori, S., Baldwin, P., and Sridhar, S. (2015) PARP inhibitors: A new era of targeted therapy. *Maturitas* 81, 5–9.

(11) Liu, J. F., Konstantinopoulos, P. A., and Matulonis, U. A. (2014) PARP inhibitors in ovarian cancer: Current status and future promise. *Gynecol. Oncol.* 133, 362–369.

(12) Barkauskaite, E., Jankevicius, G., and Ahel, I. (2015) Structures and Mechanisms of Enzymes Employed in the Synthesis and Degradation of PARP-Dependent Protein ADP-Ribosylation. *Mol. Cell.*

(13) Langelier, M. F., Planck, J. L., Roy, S., and Pascal, J. M. (2011) Crystal structures of poly(ADP-ribose) polymerase-1 (PARP-1) zinc fingers bound to DNA: Structural and functional insights into DNA-dependent PARP-1 activity. *J. Biol. Chem.* 286, 10690–10701.

(14) Eustermann, S., Wu, W. F., Langelier, M. F., Yang, J. C., Easton, L. E., Riccio, A. A., Pascal, J. M., and Neuhaus, D. (2015) Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1. *Mol. Cell.* 60, 742–754.

(15) Langelier, M.-F., Planck, J. L., Roy, S., and Pascal, J. M. (2012) Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1. *Science* (80-. ). 336, 728–732.

(16) Langelier, M.-F., Zandarashvili, L., Aguier, P. M., Black, B. E., and Pascal, J. M. (2018) NAD+ analog reveals PARP-1 substrate-blocking mechanism and allosteric communication from catalytic center to DNA-binding domains. *Nat. Commun.* 9, 844.

(17) Dawicki-McKenna, J. M., Langelier, M. F., DeNizio, J. E., Riccio, A. A., Caò, C. D., Karch, K. R., McCauley, M., Steffen, J. D., Black, B. E., and Pascal, J. M. (2015) PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain. *Mol. Cell.* 60, 755–768.

(18) de Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., Walztzinger, C., Chambon, P., and de Murcia, G. (1997) Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. *Proc. Natl. Acad. Sci. U. S. A.* 94, 7303–7.

(19) Langelier, M.-F., Riccio, A. A., and Pascal, J. M. (2014) PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. *Nucleic Acids Res.* 42, 7762–7775.

(20) Kim, M. Y., Mauro, S., Gévry, N., Lis, J. T., and Kraus, W. L. (2004) NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. *Cell* 119, 803–814.

(21) Clark, N. J., Kramer, M., Muthurajan, U. M., and Luger, K. (2012) Alternative modes of binding of poly(ADP-ribose) polymerase 1 to free DNA and nucleosomes. *J. Biol. Chem.* 287, 32430–9.

(22) Muthurajan, U. M., Hepler, M. R. D., Hieb, A. R., Clark, N. J., Kramer, M., Yao, T., and Luger, K. (2014) Autommomification switches PARP-1 function from chromatin architectural protein to histone chaperone. *Proc. Natl. Acad. Sci. U. S. A.* 111, 12752–12757.

(23) Sukhanova, M. V., Abrakh, S., Joshi, V., Pastre, D., Kutuzov, M. M., Anarbaev, R. O., Curmi, P. A., Hamon, L., and Lavrik, O. I. (2015) Single molecule detection of PARP1 and PARP2 interaction with DNA strand breaks and their poly(ADP-ribosyl)ation using high-resolution AFM imaging. *Nucleic Acids Res.* 44, 1–12.

(24) Liu, L., Kong, M., Gassman, N. R., Freudenthal, B. D., Prasad, R., Zhen, S., Watkins, S. C., Wilson, S. H., and Van Houten, B. (2017) PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARYlation or in the presence of APE1. *Nucleic Acids Res.* 45, 12834–12847.
(25) Mirny, L., Slutsky, M., Wunderlich, Z., Tafvizi, A., Leith, J., and Kosmrlj, A. (2009) How a protein searches for its site on DNA: The mechanism of facilitated diffusion. J. Phys. A Math. Theor. 42, 1–23.
(26) Zandarashvili, L., Esadze, A., Vuzman, D., Kemme, C. A., Levy, Y., and Iwahara, J. (2015) Balancing between affinity and speed in target DNA search by zinc-finger proteins via modulation of dynamic conformational ensemble. Proc. Natl. Acad. Sci. 112, E5142–E5149.
(27) Halford, S. E., and Marko, J. F. (2004) How do site-specific DNA-binding proteins find their targets? Nucleic Acids Res. 32, 3040–3052.
(28) Krebs, J., Goldstein, E., and Kilpatrick, S. (2017) Lewin’s Gene XI. Burlington, MA.
(29) Mortusewicz, O., Amé, J. C., Schreiber, V., and Leonhardt, H. (2007) Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res. 35, 7665–7675.
(30) Berg, O. G., Winter, R. B., and von Hippel, P. H. (1981) Diffusion-driven mechanisms of protein translocation on nucleic acids. 1. Models and theory. Biochemistry 20, 6929–6948.
(31) Iwahara, J., Zweckstetter, M., and Clore, G. M. (2006) NMR structural and kinetic characterization of a homeodomain diffusing and hopping on nonspecific DNA. Proc. Natl. Acad. Sci. U. S. A. 103, 15062–15067.
(32) Doucleff, M., and Clore, G. M. (2008) Global jumping and domain-specific intersegment transfer between DNA cognate sites of the multidomain transcription factor Oct-1. Proc. Natl. Acad. Sci. 105, 13871–13876.
(33) Brown, J. S., Kaye, S. B., and Yap, T. A. (2016) PARP inhibitors: the race is on. Br. J. Cancer 114, 713–715.
(34) Shen, Y., Aoyagi-scharber, M., and Wang, B. (2015) Minireview Trapping Poly ( ADP-Ribose ) Polymerase. J. Pharmacol. Exp. Ther. 446–457.
(35) Murali, J., Huang, S. Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshov, J. H., Ji, J., Takeda, S., and Pommier, Y. (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588–5599.
(36) Pommier, Y., O’Connor, M. J., and De Bono, J. (2016) Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci. Transl. Med. 8, 1–8.
(37) Hopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., Stolarik, D. F., Osterling, D. J., Johnson, E. F., and Maag, D. (2015) Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors. Mol. Cancer Res. 13, 1465–1477.
(38) Hansson, M. D., Rzeznicka, K., Rosenback, M., Hansson, M., and Sirijovski, N. (2008) PCR-mediated deletion of plasmid DNA. Anal. Biochem. 375, 373–375.
(39) Langelier, M.-F., Planck, J. L., Servent, K. M., and Pascal, J. M. (2011) Purification of Human PARP-1 and PARP-1 Domains from Escherichia coli for Structural and Biochemical Analysis, in Methods in Molecular Biology, pp 209–226.
(40) Langelier, M.-F., Ruhl, D. D., Planck, J. L., Kraus, W. L., and Pascal, J. M. (2010) The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. J. Biol. Chem. 285, 18877–18887.
(41) Record, MT, J., J.-H., H., and Fisher, M. (1991) Analysis of equilibrium and kinetic measurements to determine thermodynamic origins of stability and specificity and mechanism of formation of site- specific complexes between proteins and helical DNA. Methods Enzymol. 208, 291–343.
(42) Aleksandrov, R., Dotchev, A., Poser, I., Krastev, D., Georgiev, G., Panova, G., Babukov, Y., Danovski, G., Dyankova, T., Hubatsch, L., Ivanova, A., Atemin, A., Nedelcheva-Veleva, M. N., Hasse, S., Sarov, M., Buchholz, F., Hyman, A. A., Grill, S. W., and Stoynov, S. S. (2018) Protein Dynamics in Complex DNA Lesions. Mol. Cell 69, 1046–1061.e5.
(43) Biro, F. N., Zhai, J., Doucette, C. W., and Hingorani, M. M. (2010) Application of Stopped-
flow Kinetics Methods to Investigate the Mechanism of Action of a DNA Repair Protein. J. Vis. Exp. 1–9.

(44) Johnson, R. S., and Chester, R. E. (1998) Stopped-flow Kinetic Analysis of the Interaction of Escherichia coli RNA Polymerase with the Bacteriophage T7 A1 Promoter.

(45) Lukina, M. V., Koval, V. V., Lomzov, A. A., Zharkov, D. O., and Fedorova, O. S. (2017) Global DNA dynamics of 8-oxoguanine repair by human OGG1 revealed by stopped-flow kinetics and molecular dynamics simulation. Mol. BioSyst. 13, 1954–1966.

(46) Ferreira, D. U., and De Prat-Gay, G. (2003) A protein-DNA binding mechanism proceeds through multi-state or two-state parallel pathways. J. Mol. Biol. 331, 89–99.

(47) Halford, S. E. (2009) An end to 40 years of mistakes in DNA–protein association kinetics? Biochem. Soc. Trans. 37, 343–348.

(48) Vuzman, D., Azia, A., and Levy, Y. (2010) Searching DNA via a “Monkey Bar” Mechanism: The Significance of Disordered Tails. J. Mol. Biol. 396, 674–684.

(49) Vuzman, D., Polonsky, M., and Levy, Y. (2010) Facilitated DNA search by multidomain transcription factors: Cross talk via a flexible linker. Biophys. J. 99, 1202–1211.

(50) Fried, M. G., and Crothers, D. M. (1984) Kinetics and mechanism in the reaction of gene regulatory proteins with DNA. J. Mol. Biol. 172, 263–82.

(51) Lieberman, B. A., and Nordeen, S. K. (1997) DNA intersegment transfer, how steroid receptors search for a target site. J. Biol. Chem. 272, 1061–1068.
**Scheme 1**

\[ \text{P1} \quad \overset{k_1}{\rightleftharpoons} \quad \text{P1} \bullet \text{DNA}^* \]

**Scheme 2**

\[ \text{P1} \bullet \text{DNA}^* \quad \overset{k_1}{\rightleftharpoons} \quad \text{P1} \quad \overset{k'_1}{\rightleftharpoons} \quad \text{P1} \bullet \text{DNA}^* \]

**Scheme 3**

\[ \text{P1} \bullet \text{DNA}^* \quad \overset{k_2}{\rightleftharpoons} \quad \text{DNA} \bullet \text{P1} \bullet \text{DNA}^* \quad \overset{k_3}{\rightleftharpoons} \quad \text{P1} \bullet \text{DNA} \]
Figure 1: A) Schematic of the domains of PARP1; B) DNA binding domains (Zn1, green, Zn3 gray, and WGR, blue) of PARP1 engaging a DNA DSB (red). Residues R34 and F44 of the phosphate backbone grip and the base stacking loop in the Zn1 domain are shown in yellow and W589 in the WGR domain is shown in light blue. Coordinates were taken from 1dgy.
Figure 2: A) Representative measurement of PARP1 association with DNA as monitored by fluorescence anisotropy. Shown are the data in the absence of PARP1 (blue) and in the presence of 83 nM PARP1 (red). The black line shows a first-order exponential fit to the data and the residuals (r) from this fit are shown above. The inset shows a replot of $k_{obs}$ vs. varying concentrations of PARP1. B) Global fitting of three representative concentrations of PARP1 using the mechanism in Scheme 1: 50 nM in blue, 83 nM in green and 133 nM in red. Residuals (r) for the three concentrations are shown in the corresponding colors above.
Figure 3: Representative measurement of PARP1 dissociation from DNA as monitored by fluorescence anisotropy. Shown are the data in the absence of competitor DNA (in blue) and in the presence of 2.2 μM (green) and 4 μM DNA (red). The black line shows a first-order exponential fit to the data and the residuals from these fits are shown in the corresponding colors above. The inset shows a replot of $k_{\text{obs}}$ vs. varying concentrations of competitor DNA.
Figure 4: PARP1 dissociation from DNA as monitored by fluorescence anisotropy. Global fitting of six representative concentrations of competitor DNA using the mechanism in Scheme 3: 76 nM (light green), 149 nM (blue), 225 nM (red), 398 nM (violet), 1 µM (dark green), and 4 µM (brown). Residuals for the seven concentrations are shown overlaid in the corresponding colors above.
Figure 5: PARP1 dissociation from DNA as monitored by fluorescence anisotropy. Global fitting of three representative concentrations of competitor DNA using the mechanism in Scheme 2: 0.4 µM in blue, 1.3 µM in green, and 4 µM in red for A) DWGR and B) W589A. Residuals for the three concentrations are shown overlaid in the corresponding colors above.
Figure 6: PARP1 dissociation from DNA as monitored by fluorescence anisotropy in the presence of various inhibitors of PARP1. A) Apparent $k_{\text{obs}}$ at 1 µM competitor DNA using four different inhibitors (50 nM) (ola = olaparib, veli = veliparib, nira = niraparib, tala = talazoparib). B) Apparent $k_{\text{obs}}$ at 1 – 4000 nM competitor DNA for PARP1 alone (red) and PARP1 the presence of 50 nM talazoparib (blue).
Figure 7: Model for the monkey bar mechanism for PARP1 depicting the proposed role of the WGR domain in capturing the second DNA strand prior to release of the originally bound DNA strand (labeled with fluorescein = starred) and subsequent re-arrangement around the second DNA.
Supp. Fig 1
Supp. Fig 2
Supp. Fig 3
Supp. Fig 4C

[Graph showing a plot with axes labeled 'time (s)' and 'bound p18mer* (µM)', with data points scattered across the graph and a legend indicating different colors for each data set.

The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

bioRxiv preprint doi: https://doi.org/10.1101/317651; this version posted May 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Supp. Fig 5B

bound p18mer* (µM) vs. time (s)

-0.02 0 0.02 0.01 0.1 1

CC-BY 4.0 International license

The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

bioRxiv preprint doi: https://doi.org/10.1101/317651; this version posted May 18, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Supp. Fig 6